Abstract
Colgate-Palmolive will report quarterly results on May 1, 2026 Pre-Market, with investors tracking revenue, margins, and EPS amid expectations for continued growth and a constructive institutional stance.Market Forecast
Consensus points to stable top-line and profitability trends this quarter: total revenue is projected at 5.22 billion US dollars, up 7.20% year over year, with adjusted EPS estimated at 0.95, up 10.12% year over year; EBIT is projected at 1.11 billion US dollars, up 5.13% year over year. Forecast gross profit margin and net profit margin metrics were not provided. The main business is expected to be supported by continued pricing carryover and mix-led gains in Oral, Personal and Home Care alongside disciplined reinvestment in brand support. The most promising area remains Pet Nutrition (Hill’s), with quarterly revenue of 1.20 billion US dollars in the last period and a positive near-term outlook; year-over-year growth by segment for the last quarter was not disclosed.Last Quarter Review
Colgate-Palmolive’s most recent quarter delivered revenue of 5.23 billion US dollars, a gross profit margin of 60.15%, GAAP net profit attributable to shareholders of -37.00 million US dollars, a net profit margin of -0.71%, and adjusted EPS of 0.95, up 4.40% year over year. A notable point was the GAAP loss, which reflected one-time items recognized late in the fiscal year, including non-cash impairment and legal charges, even as underlying operating momentum and adjusted metrics remained stable. By business, Oral, Personal and Home Care contributed 4.03 billion US dollars and Pet Nutrition contributed 1.20 billion US dollars; segment-level year-over-year growth figures for the quarter were not disclosed. Quarter-on-quarter, net income declined by 105.03% given the shift from profit to a GAAP loss due to the charges.Current Quarter Outlook (with major analytical insights)
Main business: Oral, Personal and Home Care
The core Oral, Personal and Home Care franchise remains the primary determinant of quarterly revenue and earnings, with the prior quarter showing 4.03 billion US dollars from this segment. This quarter, continued pricing carryover from earlier list-price actions and mix upgrades toward premium regimens are likely to support low- to mid-single-digit organic expansion in the segment, consistent with the consolidated 7.20% revenue growth estimate. The combination of premium innovations in teeth whitening and sensitivity products and the rollout of value-added packaging is poised to sustain mix benefits; where volumes moderate, the portfolio shift can still underpin revenue quality and margin durability.Gross margin cadence for the segment hinges on the balance between commodity and packaging inputs versus productivity programs. Management has moved to execute a multi-year Strategic Growth and Productivity Program, and in this context, the quarter should benefit from structural savings related to manufacturing efficiency, SKU discipline, and packaging light‑weighting. However, input costs tied to oil-derived packaging resins are a clear near-term watch item. Sell-side commentary in recent weeks has flagged rising resin costs as a risk to household and personal care margin expansion, which could temper upside versus margin expectations even if revenue trends are favorable. On balance, Oral, Personal and Home Care should deliver a steady contribution that aligns with consensus revenue and EBIT estimates, with any margin surprise likely to be a function of how resin and freight net out against savings, and how much incremental brand investment is layered in to defend market share and support innovation.
A second variable is foreign exchange translation, given meaningful exposure in international markets. Currency was not highlighted in the consensus inputs provided, but the quarter’s reported revenue could deviate modestly from constant-currency trends if the US dollar strengthens late in the period. The company’s hedging policy and geographic revenue mix typically reduce abrupt volatility at the EPS line, but FX can still influence the reported top-line growth versus the 7.20% year-over-year forecast. Overall, the set-up suggests a quarter in which the core franchise sustains healthy growth, while the quality of earnings comes down to the balance between input costs, FX, and reinvestment timing.
Most promising business: Pet Nutrition (Hill’s)
Pet Nutrition delivered 1.20 billion US dollars last quarter and remains the most visible growth vector for 2026, reinforced by multiple large-cap brokers highlighting reacceleration in the category. This quarter, Hill’s should benefit from premiumization across therapeutic and science-based diets, continued distribution strength in veterinary channels, and early momentum from adjacency initiatives. The acquisition of Prime100 in Australia, while small relative to global Pet Nutrition, signals a targeted expansion into higher-value formats and may incrementally assist growth rates in the Asia-Pacific region over time. Even without sizable M&A impact this quarter, the existing product set and channel execution are expected to underpin above-company-average growth for Pet Nutrition.The near-term debate revolves around volume normalization after several rounds of pricing across the category and how elasticity unfolds across therapeutic formulas compared with mass-market pet foods. Hill’s historical focus on clinical nutrition and prescription-based offerings typically yields a more resilient demand profile, but the quarter’s performance will still depend on clinic traffic, prescription pull-through, and stable inventory positions at key partners. The segment’s margin mix also tends to be supportive for consolidated EBIT, which aligns with the consensus projection of 1.11 billion US dollars of EBIT for the company; upside vs. that number would likely require clean execution in Pet Nutrition with limited promotional step-up.
Input costs matter here as well, though the basket differs from household care. Protein, grains, and specialty ingredients have been comparatively manageable of late, but packaging dynamics and logistics can still swing quarterly flow-through. Given the backdrop of disciplined cost control, measured innovation spend, and continued premium mix, Pet Nutrition is positioned to remain the brightest spot in the company’s portfolio this quarter, even as absolute growth moderates from prior-year peaks in the broader pet category.
Key stock-price drivers this quarter
The first stock-price lever is gross margin direction and clarity that last quarter’s one-time charges have been fully absorbed. With GAAP net profit swinging to a small loss last quarter, investors will watch for a clean quarter with no additional impairment or litigation costs, and for the gross margin to hold near the prior 60.15% level despite resin headwinds. Any demonstration that savings from the Strategic Growth and Productivity Program outpace input inflation would likely be taken positively, especially if accompanied by disciplined working capital and cash conversion.A second driver is the translation from organic growth to reported EPS, especially given the 0.95 adjusted EPS estimate, up 10.12% year over year. The degree of reinvestment in media and R&D to back innovation will influence operating leverage; modest upside to EBIT versus the 1.11 billion US dollars projection could be achieved if mix benefits persist and overhead productivity continues to improve. Conversely, a heavier-than-expected advertising and promotion cadence could hold back near-term EPS, even if it strengthens 2H momentum.
The third driver is FX and emerging-market execution, which can augment or dilute the reported growth rate versus constant currency. Although consensus does not embed a specific margin forecast, investors will watch the revenue translation against the 5.22 billion US dollars estimate and the EBIT line, where cost discipline can counterbalance any FX drag. A clear update on the cadence of emerging-market pricing roll-off and volume stabilization would help frame the sustainability of the 7.20% top-line growth outlook. Together, these factors suggest share-price sensitivity to incremental data on margin resilience, one-time items, and the balance of growth vs. reinvestment.
Analyst Opinions
Across published views since January 1, 2026, the balance of opinion skews clearly positive: among directional calls, bullish vs. bearish stands at 100% vs. 0%, with a sizable cohort of neutral/hold ratings alongside. Multiple well-regarded brokers maintain favorable stances anchored in Pet Nutrition momentum, steady execution in the core franchise, and a constructive margin pathway despite packaging resin headwinds. This tilt underpins the “predominantly bullish” institutional characterization used in our title.Several institutions have reinforced their positive stance with updated targets. Morgan Stanley reiterated an Overweight/Buy view and recently adjusted its target to 95.00 US dollars while emphasizing reacceleration from Pet Nutrition and innovation-led growth across the portfolio. Bank of America maintained a Buy rating, citing premium-valued emerging markets exposure and Hill’s strength as pillars for upside into 2026. RBC remains positive with an Outperform/Buy stance even after trimming its price target to 102.00 US dollars, framing the cut as valuation/housekeeping rather than a change in thesis. UBS kept a Buy rating while adjusting its target to 98.00 US dollars, referencing healthy execution and a supportive margin trajectory. Deutsche Bank upgraded the shares to Buy with a 98.00 US dollars target, crediting improved growth cadence and visibility. Redburn moved to Buy and lifted its target to 100.00 US dollars, highlighting stronger medium-term drivers across key categories.
Neutral voices remain attentive to risks, but they do not outweigh the bullish cohort. Wells Fargo has maintained Hold ratings with targets clustered around the 94.00–100.00 US dollars range, citing a balanced risk-reward near term. Jefferies maintained Hold with an 88.00 US dollars target, reflecting a more conservative stance on valuation and input-cost sensitivities. TD Cowen shifted to Hold from Buy and flagged rising resin costs tied to geopolitical developments as a margin risk, which is an important check on near-term enthusiasm but falls short of a bearish call. Barclays positioned the shares at Equalweight with a reduced target of 79.00 US dollars, underscoring the valuation and cost discussion. While these neutral takes moderate expectations for a sharp re-rating, they do not contradict the broader buy-side consensus that fundamentals are improving and that the portfolio, led by Hill’s, can deliver above-peer growth at stable margins.
From a quarter-specific lens, the bullish camp’s core arguments center on three points. First, they expect mid-single-digit organic growth across the portfolio to translate into high-single-digit reported revenue growth near the 7.20% forecast, with incremental mix support from premium oral care and therapeutic pet nutrition. Second, they anticipate margin resilience as productivity initiatives offset much of the resin and packaging pressure, enabling incremental operating leverage; even if advertising investment steps up, EBIT near 1.11 billion US dollars is viewed as attainable. Third, they see improved visibility on non-recurring charges, which should allow GAAP results to better reflect underlying performance after the prior-quarter impairment and legal items. On this basis, bullish analysts generally view the quarter as an opportunity to confirm an improving earnings quality trend, with upside optionality from Hill’s momentum, geographic execution, and disciplined cost control.
In summary, the institutional majority is aligned with a constructive case for Colgate-Palmolive into this print: consensus revenue of 5.22 billion US dollars and adjusted EPS of 0.95 are seen as achievable, EBIT near 1.11 billion US dollars appears well supported, and the risk-reward balance hinges on how effectively cost savings and mix can neutralize resin inflation and any FX drag. The market will be particularly sensitive to signs that one-time charges have normalized, that Pet Nutrition’s growth remains robust, and that reinvestment remains disciplined enough to sustain progress in the back half of the year without compromising near-term earnings delivery.
Comments